Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

Suzanne L. Topalian, MD
Published: Wednesday, Nov 16, 2016


Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).
 
Researchers are looking beyond PD-L1 expression as a biomarker for anti-PD-1 agents and instead considering how cancer genetics might play a role, says Topalian.
 
 It is possible that there are genetic markers in the tumor that can help identify patients likely to respond to PD-1 agents.
 
One example of this can be seen in MSI-high (MSI-H) in CRC, says Topalian. CRC patients with defects in DNA mismatch repair mechanisms often have a high-mutational burden.
 
The MSI test is one test that is commonly used to determine if patients have this mismatch repair detect. These patients are very likely to respond to anti-PD-1 therapy, probably because all of the mutations in their tumors create new proteins that can be recognized by a very risk immune response.
 

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).
 
Researchers are looking beyond PD-L1 expression as a biomarker for anti-PD-1 agents and instead considering how cancer genetics might play a role, says Topalian.
 
 It is possible that there are genetic markers in the tumor that can help identify patients likely to respond to PD-1 agents.
 
One example of this can be seen in MSI-high (MSI-H) in CRC, says Topalian. CRC patients with defects in DNA mismatch repair mechanisms often have a high-mutational burden.
 
The MSI test is one test that is commonly used to determine if patients have this mismatch repair detect. These patients are very likely to respond to anti-PD-1 therapy, probably because all of the mutations in their tumors create new proteins that can be recognized by a very risk immune response.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x